Aclarion to Deploy Nociscan in BMAC Spine Trial at Weill Cornell
Aclarion has signed an agreement to introduce its Nociscan SaaS platform in a bone marrow aspirate stem cell concentrate trial at Weill Cornell Medicine’s Och Spine. The study will assess how BMAC dose and quantity affect functional outcomes and pain in osteoarthritis and degenerative disc disease patients.
1. Commercial Agreement Details
Aclarion has entered a commercial agreement to supply its Nociscan platform to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian, enabling the technology’s integration into a multidisciplinary spine program led by Dr. Jaspal Ricky Singh.
2. Trial Design and Objectives
Under IRB Protocol No. 22-06024915, the “Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate for Osteoarthritis and Degenerative Disc Disease” will evaluate whether varying BMAC doses and volumes influence patient-reported function and pain, with Nociscan assessments for select spine patients.
3. Nociscan Platform Overview
Nociscan is a SaaS solution utilizing magnetic resonance spectroscopy and AI-based algorithms to noninvasively quantify disc biomarkers, distinguishing painful from nonpainful lumbar discs and guiding targeted treatments to improve clinical outcomes in chronic low back pain patients.